Exhibit
99.1
SOPHiA
GENETICS Publishes Results of 2024 Annual General Meeting
Shareholders
adopt all proposals at Annual General Meeting
Boston,
US and Rolle, Switzerland, June 24, 2024 – SOPHiA GENETICS SA (Nasdaq: SOPH), a healthcare
technology company and a leader in data-driven medicine, is pleased to announce
that its annual general meeting of shareholders (the “AGM”) was held at the Company’s headquarters, La Piece
12, 1180 Rolle/VD, Switzerland, earlier today at 14:00 CEST (8:00 a.m. EDT).
The Company’s shareholders
have adopted all proposals presented at the AGM. The AGM minutes and detailed voting results by agenda item will be published on the
Company’s website in the Investors section. They will
also be filed with the U.S. Securities and Exchange Commission on Form 6-K.
The Company would like
to thank all shareholders represented for their votes and their valued commitment and support.
For more information
on SOPHiA GENETICS, visit SOPHiAGENETICS.com
and connect on LinkedIn.
# # #
About
SOPHiA GENETICS
SOPHiA
GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using
AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a
platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of
hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com
and connect with us on LinkedIn.
Forward-Looking
Statements
This
press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts
contained in this press release, including statements regarding SOPHiA GENETICS’ future results of operations and financial position,
business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future
operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS’ management’s beliefs
and assumptions and on information currently available to the company’s management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including
those described in the company’s filings with the U.S. Securities and Exchange Commission. No assurance can be given that such
future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly
disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change
in the company’s expectations or any change in events, conditions, or circumstances on which such statements are based, unless
required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such
forward-looking statements.
Investors
Contact:
Kellen Sanger
IR@sophiagenetics.com
Media
Contact:
Kelly Katapodis
media@sophiagenetics.com
